Natera’s Signatera earns TIME recognition for Natera stock
Published on 10/17/2026 at 11:01 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSRecent Signatera developments
- Natera announced the TIME recognition for Signatera on October 15, 2026.
- Natera announced enrollment in a melanoma trial on October 7, 2026.
- Signatera is supported by more than 200 peer-reviewed publications and used by more than 55 percent of U.S. oncologists.
Natera’s Signatera molecular residual disease test was named to TIME’s Best Inventions of 2026 list on October 15, 2026, according to a Natera release. The company said the test was recognized in TIME’s Medical & Healthcare category.
Market context: Market report Nasdaq Composite.
Weekend trading context
The Lang & Schwarz page for Natera showed a recorded price of EUR 350.10 on October 16, 2026, at 10:59 p.m. CEST. The next price is shown from the start of trading by the continuously updated real-time quote of Natera stock.
Recent company developments
On October 7, 2026, Natera announced enrollment of the first patients in a Signatera-guided melanoma trial sponsored by NYU Langone Health, as described in the company’s release. The study evaluates whether molecular residual disease detection can guide treatment escalation for patients with advanced or metastatic melanoma. Its primary endpoint is progression-free survival.
Natera said in its October 15 release that Signatera is supported by more than 200 peer-reviewed publications and is used by more than 55 percent of oncologists in the United States. The company also said the test has been named to Fortune’s Future 120 in October 2026.
Next Xetra session
The next Xetra session follows the weekend trading period. No company event date for that session was established by the cited Natera releases.
